Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. ImmunoGen, Inc.
  6. Summary
    IMGN   US45253H1014

IMMUNOGEN, INC.

(IMGN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
5.78(c) 5.85(c) 5.81(c) 5.83(c) 5.9(c) Last
1 457 243 839 145 776 366 617 046 851 169 Volume
-0.17% +1.21% -0.68% +0.34% +1.20% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 70,6 M - -
Net income 2021 -146 M - -
Net cash position 2021 246 M - -
P/E ratio 2021 -8,14x
Yield 2021 -
Sales 2022 70,6 M - -
Net income 2022 -179 M - -
Net cash position 2022 162 M - -
P/E ratio 2022 -6,97x
Yield 2022 -
Capitalization 1 194 M 1 194 M -
EV / Sales 2021 13,4x
EV / Sales 2022 14,6x
Nbr of Employees 79
Free-Float 99,5%
More Financials
Company
ImmunoGen, Inc. is a clinical-stage biotechnology company focused on developing the antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of its potent anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates... 
Sector
Biotechnology & Medical Research
Calendar
10/29 | 06:30amEarnings Release
More about the company
Ratings of ImmunoGen, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about IMMUNOGEN, INC.
10/14IMMUNOGEN : Announces Conference Call to Discuss Its Third Quarter 2021 Operating Results
BU
10/01IMMUNOGEN : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
09/23IMMUNOGEN, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
09/22IMMUNOGEN : Appoints Helen M. Thackray, MD to its Board of Directors
BU
09/22ImmunoGen Inc. Appoints Helen M. Thackray, MD to its Board of Directors
CI
08/12IMMUNOGEN : Securities Purchase Agreement (Form 8-K)
PU
08/12IMMUNOGEN, INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Fi..
AQ
08/02IMMUNOGEN : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
07/30IMMUNOGEN : Management's Discussion and Analysis of Financial Condition and Results of Ope..
AQ
07/30IMMUNOGEN : Reports Recent Progress and Second Quarter 2021 Financial Results (Form 8-K)
PU
07/30IMMUNOGEN : Posts Wider Q2 Loss, Higher Revenue
MT
07/30IMMUNOGEN : Q2 Earnings Snapshot
AQ
07/30IMMUNOGEN, INC. : Results of Operations and Financial Condition, Financial Statements and ..
AQ
07/30Immunogen, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
07/30IMMUNOGEN : Earnings Flash (IMGN) IMMUNOGEN Posts Q2 Revenue $16.9M
MT
More news
News in other languages on IMMUNOGEN, INC.
04/19CELYAD : nomination d'un nouveau directeur médical
2020EN DIRECT DES MARCHES : Air Liquide, Sanofi, SES, Albioma, Qiagen, Swiss Re, Xerox, Apple...
2019Les valeurs à suivre lundi à Wall Street
2018Les valeurs à suivre à Wall Street
2015Wall Street finit en hausse une séance à nouveau instable
More news
Analyst Recommendations on IMMUNOGEN, INC.
More recommendations
Chart IMMUNOGEN, INC.
Duration : Period :
ImmunoGen, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IMMUNOGEN, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 5,90 $
Average target price 9,69 $
Spread / Average Target 64,2%
EPS Revisions
Managers and Directors
Mark Joseph Enyedy President, Chief Executive Officer & Director
Susan Altschuller Chief Financial Officer & Senior Vice President
Stephen C. McCluski Chairman
Anna Berkenblit Chief Medical Officer & Senior Vice President
Thomas Ryll Senior Vice President-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
IMMUNOGEN, INC.-9.61%1 194
MODERNA, INC.212.57%131 807
LONZA GROUP AG32.74%61 177
IQVIA HOLDINGS INC.43.38%49 092
SEAGEN INC.-2.12%31 189
CELLTRION, INC.-38.86%25 455